CJC-1295 With DAC vs No DAC: Differences and Research
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
What is the difference between CJC-1295 with DAC and No DAC? DAC means drug affinity complex: a modification that allows the peptide to attach to albumin, a blood protein. “No DAC” or “without DAC” indicates the absence of that modification. FDA treats the DAC and non-DAC molecules as distinct, so findings for the long-acting DAC compound cannot simply be assigned to material labeled No DAC. FDA molecular-identity discussion
Names also vary between research papers and supplier listings. This comparison explains the DAC distinction, MOD GRF 1-29 naming and half-life claims using two selected 2006 human reports and FDA sources. It does not establish the identity of any supplied vial or provide a complete review of the current literature.
At a glance:
Establish the studied molecule before interpreting its results.
Changes in blood hormones are not the same as demonstrated health benefits.
Findings for one construct do not validate a similarly named vial or blend.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. Source-access limits appear below.

1. What does DAC change in CJC-1295 research?
The early human work describes CJC-1295 as an analog, or modified version, of growth hormone-releasing hormone (GHRH). The widely cited long-acting research concerns the albumin-binding construct. A paper may call it simply “CJC-1295,” without putting “with DAC” in the title. Check the material description before matching that paper to a No-DAC listing. Clinical study context, albumin-binding study description
DAC means drug affinity complex. FDA's December 2024 briefing distinguishes CJC-1295 from CJC-1295 DAC and their salt forms. It treats the DAC and non-DAC active molecules as non-interchangeable. The DAC modification permits chemical attachment to albumin, a protein in blood. FDA cautions against transferring the DAC construct's pharmacological profile to material without that modification. FDA briefing, identity and nonclinical sections — PDF
For a label saying “No DAC,” start with the reported sequence and modification details, not an assumed equivalence. This guide does not authenticate what any seller means by that label or verify the contents of our own inventory.
Removing a distinguishing word from a name cannot make the evidence transferable. A paper's methods and material description must match the substance being discussed.
Comparison point | CJC-1295 with DAC | Material labeled CJC-1295 No DAC |
|---|---|---|
Identity distinction | Includes the albumin-binding DAC modification | Lacks that modification; obtain the exact sequence and chemical form |
Names encountered | CJC-1295 with DAC, CJC-1295 DAC, or simply CJC-1295 in the cited human papers | CJC-1295 No DAC, without DAC, and listings also using MOD GRF 1-29 |
Half-life evidence in the cited trials | A multi-day estimate for the studied long-acting compound | Those trials do not establish a No-DAC half-life or a direct comparison |
What the name establishes | A construct to check against the paper's methods | A label to investigate, not proof of equivalence to the studied DAC construct |
Evidence transfer | Read findings for the exact construct and study population | Do not assign the DAC construct's pharmacological profile to non-DAC material |
Documentation needed | Sequence, modifications, form, sample identity and lot | The same identity and lot checks, with the absence of DAC documented |
This comparison draws on the FDA briefing's identity discussion and the Teichman clinical-study abstract. It does not identify the contents of a current catalog vial or rank either form as clinically better.
Where does MOD GRF 1-29 fit?
Readers searching for MOD GRF 1-29 often encounter listings also labeled CJC-1295 No DAC. FDA's 2024 briefing records examples of that marketplace naming, while distinguishing DAC and non-DAC substances by their actual structures. A shared listing name is not analytical confirmation that two supplied materials match. FDA briefing, identity discussion and marketplace references
For a useful comparison, obtain the sequence, modification details, chemical form and lot-linked identity result. Then compare those details with the material in the original study. The marketplace references explain why these terms appear together in searches; they do not authenticate a catalog lot or turn a historical briefing into a current approval decision.
2. How do DAC and No DAC half-life claims compare?
The Teichman study abstract reports an estimated half-life of 5.8–8.1 days for the studied long-acting CJC-1295 compound. This is a result for that material and study setting, not a half-life assigned to every product called CJC-1295. Original half-life report
The two human reports discussed here do not provide a head-to-head DAC versus No-DAC comparison. We therefore do not use them to assign a precise number of minutes to No DAC. FDA's briefing also notes that a direct half-life comparison with the non-DAC molecule would be needed to support the proposed stability difference. FDA pharmacokinetics discussion, printed page 27 — PDF
Half-life describes the time over which a measured concentration falls by half. It is different from the duration of a hormonal response and does not, by itself, establish a clinical benefit or an administration schedule.
Teichman and colleagues reported two randomized, double-blind, placebo-controlled trials lasting 28 and 49 days. Participants were healthy adults aged 21–61. The researchers measured growth hormone, or GH, and insulin-like growth factor I, or IGF-I, alongside the compound's behavior in the body. They reported sustained increases in these blood measurements and no serious adverse reactions in those trials. Teichman and colleagues, 2006 — abstract
That is evidence about measured hormonal responses in a defined study setting. It does not by itself establish improvements in sleep, physical function, or long-term health. A short trial reporting no serious reaction also cannot rule out uncommon or delayed harms.
An important reading habit is to keep the endpoint beside the finding. Here, the endpoint was largely a laboratory measurement, not a demonstrated everyday benefit. Avoid silently replacing one with the other.
3. Does preserved pulsatility mean an unchanged hormone pattern?
No. In a separate report, Ionescu and Frohman examined overnight GH measurements in healthy men before and one week after the albumin-binding construct. They found that pulse frequency and magnitude were unchanged, while the lowest levels between pulses and average GH increased. IGF-I also increased. Ionescu and Frohman, 2006 — abstract
A pulse is a temporary rise in hormone secretion; a trough is the lower level between rises. Keeping pulses does not mean every part of the pattern stayed unchanged. Nor does it demonstrate that a changed pattern is beneficial or safe for another population.
These two reports also share an investigator. They answer related but different questions and should not be described as two independent demonstrations of a general wellness benefit.
4. What safety context belongs beside the findings?
FDA's compounding-risk page, checked November 16, 2026, identifies immune-response and impurity-characterization concerns for CJC-1295. It also reports serious associated events, including increased heart rate and a body-wide blood-vessel dilation reaction, while noting limited clinical data. The entry is under withdrawn nominations. Withdrawal is not evidence that the safety concerns were resolved. FDA compounding safety context
This is compounding safety information, not a test of our catalog lots or a complete legal assessment of the storefront. Research-use wording is not scientific evidence of safety.
Is CJC-1295 No DAC safer or better than DAC?
The selected studies do not establish that comparison. Absence of DAC is an identity difference, not evidence of lower risk. Longer persistence is also not proof of better outcomes. A meaningful comparison would need the exact materials, a defined outcome and an appropriate comparative study; the cited healthy-adult hormone studies do not supply that result.
5. How can a reader avoid a false match?
Before attaching a study citation to a material record, check:
Identity: the sequence, modifications, and chemical form are documented.
Study: the material, population, comparison, and endpoint match the claim.
Scope: uncertainty and unchanged outcomes are retained.
Mixtures: evidence about separate ingredients is not presented as evidence about their combination.
For example, the two human reports discussed here concern CJC-1295, not a CJC-1295/ipamorelin blend. They do not demonstrate the performance of that mixture. This is a limit of these cited reports, not a claim that every possible combination study has been searched.
Does a CJC-1295/ipamorelin label mean No DAC?
The combined name alone does not answer the DAC question. Check the CJC component's stated identity and modifications, then match the documentation to the supplied lot. The presence of ipamorelin does not establish which CJC form was used. Our CJC-1295 and ipamorelin evidence guide separately examines combination claims.
For the separate evidence on the other ingredient, read our Ipamorelin research and endpoint guide. Ingredient studies do not establish a mixture's effects.
Can a purity percentage confirm whether DAC is present?
A purity percentage by itself is not a complete identity statement. Read the named analytical method, identified material and report scope, and ask for clarification when the modification is not established. A report for a different form or lot cannot resolve that mismatch.
For document checks, use our COA, HPLC, and mass spectrometry guide and research peptide documentation checklist. Related reading is in the research resource library.
Review method and source access
The original September 27, 2026 source check covered two original-study abstracts, selected sections of FDA's 2024 briefing, and FDA's safety page. The comparison was expanded November 16, 2026 after rechecking those abstracts, the briefing's identity, marketplace-reference and pharmacokinetics sections, and the current safety page. The full clinical papers, participant-level data, and complete funding disclosures were not reviewed. No new experiments or independent lot testing were performed. This is a selected-source update, not a systematic review or regulatory clearance.
Catalog materials are offered for lawful laboratory research only, not for human or veterinary use. This article supplies no dosing or administration instructions and makes no claim that a current product reproduces a study's results.
References
Teichman and colleagues, CJC-1295 hormone and half-life study, indexed abstract
Ionescu and Frohman, growth-hormone pulsatility study, indexed abstract
On November 19, 2026, we rechecked the two human-study abstracts and FDA's CJC-1295 safety-risk entry. The 2024 briefing and full clinical papers retain the access limits and dates stated above; this is not a new systematic search.
